Aye Aye Thike

Aye Aye Thike

Auto-generated profile, based on publicly available information

Aye Aye Thike

Department of Anatomical Pathology, Singapore General Hospital, Singapore, Singapore

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
LLLian Dee Ler
Lian Dee Ler
SUJOY GHOSHSUJOY GHOSH
SUJOY GHOSH
XCXiaoran Chai
Xiaoran Chai
ATAye Aye Thike
Aye Aye Thike
HHHong Lee Heng
Hong Lee Heng
BTBin Tean Teh
Bin Tean Teh
Trithorax-like group complex containing KDM6A acts antagonistically to Polycomb-repressive complex 2 (PRC2) containing EZH2 in maintaining the dynamics of the repression and activation of gene expression through H3K27 methylation. In urothelial bladder carcinoma, KDM6A (a H3K27 demethylase) is frequently mutated, but its functional consequences and therapeutic targetability remain unknown. About 70% of KDM6A mutations resulted in a total loss of expression and a consequent loss of demethylase function in this cancer type. Further transcriptome analysis found multiple deregulated pathways, especially PRC2/EZH2, in KDM6A-mutated urothelial bladder carcinoma. Chromatin immunoprecipitation sequencing analysis revealed enrichment of H3K27me3 at specific loci in KDM6A-null cells, including PRC2/EZH2 and their downstream targets. Consequently, we targeted EZH2 (an H3K27 methylase) and demonstrated that KDM6A-null urothelial bladder carcinoma cell lines were sensitive to EZH2 inhibition. Loss- and gain-of-function assays confirmed that cells with loss of KDM6A are vulnerable to EZH2. IGFBP3, a direct KDM6A/EZH2/H3K27me3 target, was up-regulated by EZH2 inhibition and contributed to the observed EZH2-dependent growth suppression in KDM6A-null cell lines. EZH2 inhibition delayed tumor onset in KDM6A-null cells and caused regression of KDM6A-null bladder tumors in both patient-derived and cell line xenograft models. In summary, our study demonstrates that inactivating mutations of KDM6A, which are common in urothelial bladder carcinoma, are potentially targetable by inhibiting EZH2.

1 July 2021 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
CNCedric Chuan Young Ng
Cedric Chuan Young Ng
NNNur Diyana Md Nasir
Nur Diyana Md Nasir
BLBenjamin Nathanael Loke
Benjamin Nathanael Loke
TTTimothy Kwang Yong Tay
Timothy Kwang Yong Tay
ATAye Aye Thike
Aye Aye Thike
PTPuay Hoon Tan
Puay Hoon Tan


13 August 2019 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
CLChi Peng Timothy Lai
Chi Peng Timothy Lai
JYJoe Yeong
Joe Yeong
ATAn Sen Tan
An Sen Tan
COChong Hui Clara Ong
Chong Hui Clara Ong
BLBernett Lee
Bernett Lee
PTPuay Hoon Tan
Puay Hoon Tan